Of particular note at day 56 , the RGN-259-treated group ( 12 eyes ) had 35.1 % reduction of ocular discomfort compared with vehicle control ( 6 eyes ) ( P = 0.0141 ) , and 59.1 % reduction of total corneal fluorescein staining compared with vehicle control ( P = 0.0108 ) .